Skip to main content
GH logo

GH · Guardant Health, Inc. · Documents

Track GH — free
$145.59 +0.45 (+0.31%) At close · Nov 19 Play latest call Q3 2026 earnings call transcript
Market Cap
$19.70B
Shares
135.29M
Volume · Nov 19 1.87M Avg daily vol (3M) 1.98M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $982.02M up 32.9% 10-K filed Feb 19, 2026 Quarterly report FY2026 Q3 Revenue $360.98M up 36.1% 10-Q filed Nov 5, 2026 Latest results Revenue grew 36%; 2026 guidance raised 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 16
Current report 8-K Events of Nov 11
Completes $550 Million 0% Convertible Notes Offering Due 2032

Guardant Health completed a $550 million private offering of 0% convertible senior notes due 2032. Net proceeds of approximately $538.3 million were used in part to repurchase $395.2 million of its 2027 convertible notes.

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Other events Read from the first part of this long document
3 source passages
On November 16, 2026, Guardant Health, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $550 million aggregate principal amount of 0% Convertible Senior Notes due 2032 The net proceeds from the Offering, after deducting the initial purchasers’ discounts and commissions and the Company’s estimated offering expenses, were approximately $538.3 million. The Company used approximately $501.7 million of the net proceeds from the Offering to repurchase for cash approximately $395.2 million aggregate principal amount of its existing 0% Convertible Senior Notes due 2027 Open the document at this passage
Nov 5
Earnings call
Raises 2026 revenue guidance to $1.36 to $1.37 billion

Guardant Health raised full-year 2026 revenue guidance to $1.36 to $1.37 billion, after reporting third-quarter revenue of $361.0 million; screening revenue reached $68 million and oncology revenue reached $231 million.

4 source passages
Total revenue: the transcript reads “$351 million”, but the company's 8-K filed 2026-11-05 reports $361.0 million. we're raising our full-year 2026 revenue guidance to a range of $1.36 to $1.37 billion. Screening revenue was $68 million Oncology revenue was $231 million Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 36% as Shield screening revenue surged 180%

Guardant Health reported revenue of $361.0 million for the three months ended September 30, 2026, up 36% from $265.2 million for the three months ended September 30, 2025. Shield screening revenue rose 180% to $67.6 million.

Revenue $360.98M ▲ 36.1% Net loss $124.36M Diluted EPS -$0.93
Read from the MD&A section
3 source passages
Total revenue was $361.0 million for the three months ended September 30, 2026, compared to $265.2 million for the three months ended September 30, 2025, an increase of $95.8 million, or 36%. Screening revenue was $67.6 million for the three months ended September 30, 2026, compared to $24.1 million for the three months ended September 30, 2025, an increase of $43.5 million, or 180%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 83,000 for the three months ended September 30, 2026 from approximately 24,000 for the three months ended September 30, 2025. Open the document at this passage
Nov 5
Current report 8-K
Revenue grew 36%; 2026 guidance raised

Guardant Health reported third-quarter revenue of $361.0 million, up 36%, and raised 2026 revenue guidance to $1.36 to $1.37 billion, representing 38% to 40% growth.

Financial results
2 source passages
Reported total revenue of $361.0 million, an increase of 36%, driven by: Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025. Open the document at this passage
Nov 3
Current report 8-K Events of Nov 2
Kevin R. Sayer appointed as board expands to 11

Guardant Health expanded its board to 11 by appointing Kevin R. Sayer effective November 2, 2026, and appointed Robert A. Parks Chief Accounting Officer. Sayer will receive a $500,000 restricted stock unit award and a $60,000 per year cash retainer.

Director or officer change, or executive pay
4 source passages
On November 2, 2026, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to 11 and appointed Kevin R. Sayer, 68, as a Class II director of the Company, to be effective as of November 2, 2026. On November 2, 2026, the Board appointed Robert A. Parks as Chief Accounting Officer and he assumed the role of principal accounting officer of the Company. Mr. Sayer will receive the standard compensation paid by the Company to all of its non-employee directors under the Company’s Eligible Director Compensation Program (the “Program”). Pursuant to the Program, Mr. Sayer will receive a restricted stock unit award with a value of $500,000 (the “Initial Award”). In addition, Mr. Sayer will receive a cash retainer of $60,000 per year for service as a director. Open the document at this passage
Nov 3
Current report 8-K Events of Nov 2
Co-CEOs Receive 465,413 Target PSUs Each, Contingent on TSR

Guardant Health, Inc. awarded founders and Co-CEOs Helmy Eltoukhy and AmirAli Talasaz 465,413 target PSUs each, contingent on relative TSR, with 25% tied to a three-year period and 75% to a five-year period beginning June 1, 2026.

Director or officer change, or executive pay Read from the first part of this long document
4 source passages
Each Co-CEO received a grant of 465,413 PSUs at target (the “Target PSUs”). These Target PSUs will only be eligible to be earned if the Company’s total shareholder return (“TSR”) relative to the constituents of the S&P 500 Index meets or exceeds certain performance requirements over three-year and five-year performance periods, as further described below. Guardant Health, Inc. (the “Company”) ... to each of the Company’s founders and Co-Chief Executive Officers, Helmy Eltoukhy and AmirAli Talasaz (the “Co-CEOs”). Twenty-five percent (25%) of the Target PSUs are eligible to be earned based on the Company’s relative TSR over a three-year performance period beginning June 1, 2026 and ending May 31, 2029 (the “3-Year PSUs”), and the remaining 75% are eligible to be earned based on the Company’s relative TSR over a five-year performance period beginning June 1, 2026 and ending May 31, 2031 (the “5-Year PSUs”). Open the document at this passage
Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $334.98M ▲ 44.3% Net loss $120.14M Diluted EPS -$0.90
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $301.67M ▲ 48.3% Net loss $112.08M Diluted EPS -$0.85
Apr 28
Proxy statement DEF 14A Meeting Jun 17, 2026
Proxy statement AI summary on its way
Feb 19
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $982.02M ▲ 32.9% Net loss $416.28M Diluted EPS -$3.32
2025
Feb 20
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $739.02M ▲ 31.0% Net loss $436.37M Diluted EPS -$3.56
Showing 1–50 of 174 documents
Key facts CIK 1576280 CUSIP 40131M109 13F (30d) 657 filings 604 filers Visit website Investor relations